Skip to main content

IL-6R alpha Antibody (tocilizumab) - Humanized

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28034

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

ELISA, Flow Cytometry, Functional

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Human IgG1 Clone # tocilizumab

Concentration

LYOPH mg/ml

Product Specifications

Immunogen

IL-6Ra / CD126

Reactivity Notes

Predicted species reactivity: Cynomolgus

Clonality

Monoclonal

Host

Human

Isotype

IgG1

Endotoxin Level

< 0.001EU/ug,determined by LAL method.

Description

Expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.38 kDa.

Also known as 'tocilizumab'.

Upon receipt, store immediately at -20C or lower for 24 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.

Scientific Data Images for IL-6R alpha Antibody (tocilizumab) - Humanized

IL-6R alpha Antibody (tocilizumab) - Humanized

Flow Cytometry: IL-6R alpha Antibody (tocilizumab) - Humanized[NBP3-28034] -

IL-6R alpha Antibody (tocilizumab) - Humanized-induced FACS Blocking activity was evaluated using Human IL-6R CHO cells. The IC50 was approximately 1.303nM.
IL-6R alpha Antibody (tocilizumab) - Humanized

Flow Cytometry: IL-6R alpha Antibody (tocilizumab) - Humanized[NBP3-28034] -

Human IL-6R CHOs cells were stained with IL-6R alpha Antibody (tocilizumab) - Humanized and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.4525 nM.

Applications for IL-6R alpha Antibody (tocilizumab) - Humanized

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Functional

Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A purified

Reconstitution

Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

Formulation

Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)

Preservative

No Preservative

Concentration

LYOPH mg/ml

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C.

Background: IL-6R alpha

IL-6 R alpha is a transmembrane subunit of the receptor for Interleukin-6. It associates with gp130 which is a shared component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM. Soluble forms of IL-6 R alpha are generated by both alternative splicing and proteolytic cleavage. In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R alpha elicit responses from gp130-expressing cells that lack cell surface IL-6 R alpha. IL-6 plays important roles in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6, along with TNF-alpha and IL-1, drives the acute inflammatory response and the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. When dysregulated, it contributes to chronic inflammation in obesity, insulin resistance, inflammatory bowel disease, arthritis, sepsis, and atherosclerosis.

Long Name

Interleukin 6 Receptor alpha

Alternate Names

CD126, IL-6 R alpha, IL-6Ra, IL6R, IL6R alpha

Gene Symbol

IL6R

UniProt

Additional IL-6R alpha Products

Product Documents for IL-6R alpha Antibody (tocilizumab) - Humanized

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for IL-6R alpha Antibody (tocilizumab) - Humanized

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...